keyword
MENU ▼
Read by QxMD icon Read
search

Cost statin utilization

keyword
https://www.readbyqxmd.com/read/27927162/use-of-low-density-lipoprotein-particle-number-levels-as-an-aid-in-statin-treatment-decisions-for-intermediate-risk-patients-a-cost-effectiveness-analysis
#1
Dov Shiffman, Andre R Arellano, Michael P Caulfield, Judy Z Louie, Lance A Bare, James J Devlin, Olle Melander
BACKGROUND: The 2013 ACC/AHA guideline recommended either no statin therapy or moderate-intensity statin therapy (MST) for intermediate risk patients-those with 5-7.5% 10-year risk and without cardiovascular disease (CVD), hypercholesterolemia or diabetes. The guideline further suggested that the therapy choice be based on patient-clinician discussions of risks and benefits. Since low-density lipoprotein particle (LDL-P) levels were reported to be associated with CVD independently of traditional risk factors in intermediate and low risk patients, we investigated the cost-effectiveness of using LDL-P levels to identify intermediate risk patients likely to benefit from initiating or intensifying statin therapy...
December 7, 2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27836822/impact-of-cost-sharing-on-therapeutic-substitution-the-story-of-statins-in-2006
#2
Pengxiang Li, J Sanford Schwartz, Jalpa A Doshi
BACKGROUND: Cost sharing is widely used to encourage therapeutic substitution. This study aimed to examine the impact of increases in patient cost-sharing differentials for brand name and generic drugs on statin utilization on entry into the Medicare Part D coverage gap. METHOD AND RESULTS: Using 5% Medicare Chronic Condition Warehouse files from 2006, this quasi-experimental study examined patients with hyperlipidemia who filled prescriptions for atorvastatin or rosuvastatin between January and March 2006...
November 11, 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27753942/os-06-07-combining-short-and-long-term-risk-scores-in-primary-prevention-of-major-cardiovascular-disease-events-in-low-incidence-populations-an-assessment-of-clinical-utility
#3
Giovanni Veronesi, Simona Giampaoli, Francesco Gianfagna, Luigi Palmieri, Diego Vanuzzo, Guido Grassi, Giancarlo Cesana, Marco M Ferrario
OBJECTIVE: To evaluate the clinical utility of the CAMUNI-MATISS 20-year risk score, recently validated for the Italian population, as additional screening tool for individuals at "low" (ESC-SCORE Project predicted 10-year risk ≤ 1%; no preventive action), "intermediate" (ESC-SCORE 1-4%; lifestyle modification/statin treatment) and "high" risk (ESC-SCORE≥ 4% or diabetes; statin treatment) according to the Italian regulation. DESIGN AND METHOD: 40-65 years old initially CVD-free participants to 7 population-based cohorts enrolled in Northern and Central Italy between 1986 and 1996 were followed-up (median 16 years, IQR: 12-20) to the first occurrence of coronary event or ischemic stroke (fatal or non-fatal), coronary or carotid revascularizations...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27662221/cost-benefit-of-appointment-based-medication-synchronization-in-community-pharmacies
#4
Julie A Patterson, David A Holdford, Kunai Saxena
OBJECTIVES: To evaluate the cost-benefit of appointment-based medication synchronization (ABMS) offered in community pharmacies for patients taking chronic medications to prevent negative outcomes associated with hyperlipidemia, hypertension, and diabetes. STUDY DESIGN: Decision-tree analysis based on published literature and publicly available data. METHODS: Program benefits were based on linking published findings of improvements in medication adherence due to the implementation of an ABMS program to a claims-based study of disease-related medical costs associated with different levels of adherence...
September 2016: American Journal of Managed Care
https://www.readbyqxmd.com/read/27650822/%C3%AE-blockers-and-mortality-after-myocardial-infarction-in-patients-without-heart-failure-multicentre-prospective-cohort-study
#5
Etienne Puymirat, Elisabeth Riant, Nadia Aissoui, Angèle Soria, Gregory Ducrocq, Pierre Coste, Yves Cottin, Jean François Aupetit, Eric Bonnefoy, Didier Blanchard, Simon Cattan, Gabriel Steg, François Schiele, Jean Ferrières, Yves Juillière, Tabassome Simon, Nicolas Danchin
OBJECTIVE:  To assess the association between early and prolonged β blocker treatment and mortality after acute myocardial infarction. DESIGN:  Multicentre prospective cohort study. SETTING:  Nationwide French registry of Acute ST- and non-ST-elevation Myocardial Infarction (FAST-MI) (at 223 centres) at the end of 2005. PARTICIPANTS:  2679 consecutive patients with acute myocardial infarction and without heart failure or left ventricular dysfunction...
September 20, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27643337/os-06-07-combining-short-and-long-term-risk-scores-in-primary-prevention-of-major-cardiovascular-disease-events-in-low-incidence-populations-an-assessment-of-clinical-utility
#6
Giovanni Veronesi, Simona Giampaoli, Francesco Gianfagna, Luigi Palmieri, Diego Vanuzzo, Guido Grassi, Giancarlo Cesana, Marco M Ferrario
OBJECTIVE: To evaluate the clinical utility of the CAMUNI-MATISS 20-year risk score, recently validated for the Italian population, as additional screening tool for individuals at "low" (ESC-SCORE Project predicted 10-year risk ≤ 1%; no preventive action), "intermediate" (ESC-SCORE 1-4%; lifestyle modification/statin treatment) and "high" risk (ESC-SCORE≥ 4% or diabetes; statin treatment) according to the Italian regulation. DESIGN AND METHOD: 40-65 years old initially CVD-free participants to 7 population-based cohorts enrolled in Northern and Central Italy between 1986 and 1996 were followed-up (median 16 years, IQR: 12-20) to the first occurrence of coronary event or ischemic stroke (fatal or non-fatal), coronary or carotid revascularizations...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27599748/statin-adherence-rates-in-patients-utilizing-a-patient-centered-medical-home-based-pharmacy
#7
Erin M Slazak, Jessica T Kozakiewicz, Natalie S Winters, Jason R Smith, Scott V Monte
BACKGROUND: Medication nonadherence contributes to approximately US$290 billion per year in avoidable health-care spending. Statins are of particular interest because of their importance to patient outcomes, costs of treatment failure, and categorization as a Medicare star measure linked to financial reimbursement. OBJECTIVE: To evaluate statin adherence as defined by the proportion of days covered (PDC) among patients who use an embedded dispensing pharmacy in a patient-centered medical home (PCMH)...
September 6, 2016: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/27585206/the-role-of-a-coronary-artery-calcium-scan-in-type-1-diabetes
#8
Mark R Burge, R Philip Eaton, David S Schade
The coronary artery calcium (CAC) scan has recently emerged as a reproducible noninvasive test to detect asymptomatic atherosclerotic coronary artery disease. It has several advantages over the traditional cardiac stress testing modalities, including lower cost, greater sensitivity for nonobstructing coronary artery lesions, and excellent prognostic value when combined with the Framingham risk parameters. Its chief disadvantage is that it does not identify obstructing coronary artery lesions or noncalcified coronary artery plaque...
September 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27558760/medication-nonadherence-the-role-of%C3%A2-cost-community-and-individual-factors
#9
Ibrahim Abbass, Lee Revere, Jordan Mitchell, Ajit Appari
OBJECTIVE: To explain the association of out-of-pocket (OOP) cost, community-level factors, and individual characteristics on statin therapy nonadherence. DATA SOURCES: BlueCross BlueShield of Texas claims data for the period of 2008-2011. STUDY DESIGN: A retrospective cohort of 49,176 insured patients, aged 18-64 years, with at least one statin refill during 2008-2011 was analyzed. Using a weighted proportion of days covered ratio, differences between adherent and nonadherent groups are assessed using chi-squared tests, t-tests, and a clustered generalized linear model with logit link function...
August 25, 2016: Health Services Research
https://www.readbyqxmd.com/read/27455456/effect-of-prescription-drug-coupons-on-statin-utilization-and-expenditures-a-retrospective-cohort-study
#10
Matthew Daubresse, Martin Andersen, Kevin R Riggs, G Caleb Alexander
IMPORTANCE: Drug coupons are widely used, but their effects are not well understood. OBJECTIVE: To quantify the effect of coupons on statin use and expenditures. DESIGN: Retrospective cohort analysis of IMS Health LRx LifeLink database. SETTING: U.S. retail pharmacy transactions. PARTICIPANTS: Incident statin users who initiated branded atorvastatin or rosuvastatin between June 2006 and February 2013...
July 25, 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27352086/a-novel-cost-effectiveness-model-of-prescription-eicosapentaenoic-acid-extrapolated-to-secondary-prevention-of-cardiovascular-diseases-in-the-united-states
#11
Sephy Philip, Sumita Chowdhury, John R Nelson, P Benjamin Everett, Carolyn K Hulme-Lowe, Jordana K Schmier
OBJECTIVE: Given the substantial economic and health burden of cardiovascular disease and the residual cardiovascular risk that remains despite statin therapy, adjunctive therapies are needed. The purpose of this model was to estimate the cost-effectiveness of high-purity prescription eicosapentaenoic acid (EPA) omega-3 fatty acid intervention in secondary prevention of cardiovascular diseases in statin-treated patient populations extrapolated to the US. METHODS: The deterministic model utilized inputs for cardiovascular events, costs, and utilities from published sources...
October 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27324201/how-low-income-subsidy-recipients-respond-to-medicare-part-d-cost-sharing
#12
Bruce Stuart, Franklin Hendrick, Jing Xu, J Samantha Dougherty
OBJECTIVES: To determine the magnitude and mechanisms of response to Medicare Part D cost sharing by low-income subsidy (LIS) recipients using oral hypoglycemic agents (OHAs) and statins. DATA SOURCES: Medicare data for a 5 percent random sample of beneficiaries with diabetes enrolled in fee-for-service Part D drug plans in 2008. STUDY DESIGN: We evaluated the impact of differences between generic and brand cost sharing rates among cohorts of LIS and non-LIS recipients to determine if wider price spreads increased the generic dispensing rate (GDR) and reduced total drug use and cost...
June 20, 2016: Health Services Research
https://www.readbyqxmd.com/read/27266585/a-cost-effectiveness-analysis-of-over-the-counter-statins
#13
Christopher Stomberg, Margaret Albaugh, Saul Shiffman, Neeraj Sood
OBJECTIVES: To estimate the costs and benefits of over-the-counter (OTC) statins under the 2013 American College of Cardiology/American Heart Association guidelines. STUDY DESIGN: A 10-year cost-effectiveness model using a health system perspective was developed to analyze the impact of making an OTC statin drug available. METHODS: We calibrated the model by using nationally representative survey data on statin use and cardiovascular risk, data from clinical studies on the safety and efficacy of statins, and data from a study on consumer decisions to use an OTC statin...
2016: American Journal of Managed Care
https://www.readbyqxmd.com/read/27092712/cost-effectiveness-of-ldl-c-lowering-with-evolocumab-in-patients-with-high-cardiovascular-risk-in-the-united-states
#14
Shravanthi R Gandra, Guillermo Villa, Gregg C Fonarow, Mickael Lothgren, Peter Lindgren, Ransi Somaratne, Ben van Hout
Randomized trials have shown marked reductions in low-density lipoprotein cholesterol (LDL-C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added to standard of care (SOC) vs SOC alone is cost-effective in the treatment of patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic CVD (ASCVD) with or without statin intolerance and LDL-C >100 mg/dL. Using a Markov cohort state transition model, primary and recurrent CVD event rates were predicted considering population-specific trial-based mean risk factors and calibrated against observed rates in the real world...
June 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/26975917/potential-effects-of-rational-prescribing-on-national-health-care-spending-more-than-half-a-billion-dollars-in-annual-savings
#15
Jordan Littman, Roland Halil
OBJECTIVE: To estimate the cost savings that could result from implementation of a rational prescribing model for drug classes that are equivalent in terms of efficacy, toxicity, and convenience. DESIGN: The top 10 drug classes based on annual spending were gathered from the Canadian Institute for Health Information. They were reviewed for potential inclusion in the study based on the ability to compare intraclass medications. When equivalence in efficacy, toxicity, and convenience was determined from a literature review, annual prescribing data were gathered from the National Prescription Drug Utilization Information Systems Database...
March 2016: Canadian Family Physician Médecin de Famille Canadien
https://www.readbyqxmd.com/read/26788980/resource-use-and-costs-in-high-risk-symptomatic-peripheral-artery-disease-patients-with-diabetes-and-prior-acute-coronary-syndrome-a-retrospective-analysis
#16
Monica Reed Chase, Howard S Friedman, Prakash Navaratnam, Kim Heithoff, Ross J Simpson
OBJECTIVES: As the prevalence of peripheral artery disease (PAD) increases there is growing concern about the associated healthcare burden. This burden has not been well-characterized in high-risk patients with concurrent diabetes and/or acute coronary syndrome (ACS). The objective of this analysis was to assess comorbidities, medication use, outcomes, services and costs for 3 high-risk symptomatic PAD groups. METHODS: This retrospective longitudinal analysis used the MarketScan Commercial Claims and Encounters Database (2005-2013)...
2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/26707482/cost-driver-analysis-of-statin-expenditure-on-australia-s-pharmaceutical-benefits-scheme
#17
L P Thai, J R Moss, B Godman, A I Vitry
INTRODUCTION: The Australian Pharmaceutical Benefits Scheme (PBS) provides universal access to subsidized medicines. In 2013, statins as a class had the highest expenditure on the PBS. OBJECTIVES: To assess the influence of policies and drivers affecting PBS statin utilization and expenditure between 1992 and 2013. METHODS: Analyses conducted from 1992 to 2013 and over three distinct time periods, including monthly expenditure/prescription, annual utilization (calculated as Defined Daily Doses/1000 inhabitants/day) and statin strengths dispensed...
June 2016: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/26680162/optimal-strategies-for-monitoring-lipid-levels-in-patients-at-risk-or-with-cardiovascular-disease-a-systematic-review-with-statistical-and-cost-effectiveness-modelling
#18
REVIEW
Rafael Perera, Emily McFadden, Julie McLellan, Tom Lung, Philip Clarke, Teresa Pérez, Thomas Fanshawe, Andrew Dalton, Andrew Farmer, Paul Glasziou, Osamu Takahashi, John Stevens, Les Irwig, Jennifer Hirst, Sarah Stevens, Asuka Leslie, Sachiko Ohde, Gautam Deshpande, Kevin Urayama, Brian Shine, Richard Stevens
BACKGROUND: Various lipid measurements in monitoring/screening programmes can be used, alone or in cardiovascular risk scores, to guide treatment for prevention of cardiovascular disease (CVD). Because some changes in lipids are due to variability rather than true change, the value of lipid-monitoring strategies needs evaluation. OBJECTIVE: To determine clinical value and cost-effectiveness of different monitoring intervals and different lipid measures for primary and secondary prevention of CVD...
December 2015: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/26539464/effects-of-adherence-to-statin-therapy-on-health-care-outcomes-and-utilizations-in-taiwan-a-population-based-study
#19
Ying-Chun Li, Wei-Ling Huang
AIM: Good medication adherence may decrease the probability of worse outcomes and reduce unnecessary medical care costs. This study aims to evaluate medication adherence for people on statin therapy. METHODS: National health insurance databases were analyzed from January 1, 2001, to December 31, 2007. Study samples were patients of 45 years and older adults who took statin for the first time during the study period. Medication possession ratio (MPR) was measured until the patients had hospitalization or reached the three-year follow-up period...
2015: BioMed Research International
https://www.readbyqxmd.com/read/26532229/cost-utility-of-statin-in-secondary-prevention-a-propensity-score-method-of-administrative-database
#20
A Luque, M R Nobre, M T Abrahão
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
keyword
keyword
41677
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"